Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
hazard ratio | 95% confidence interval | p-value | hazard ratio | 95% confidence interval | p-value (p-value of model) | |
Cluster (CIMP vs. Non-CIMP (n = 180) | 1.182 | 0.6763–2.065 | 0.5593 | |||
Age (≥60) (n = 180) | 2.328 | 1.193–4.544 | 0.007842 | 3.693 (n = 155) | 1.634–8.349 | 0.00169 (2.475e-06) |
Polyps present (n = 138) | 2.518 | 1.03–6.155 | 0.03877 | |||
Gender (Male vs. Female) (n = 180) | 1.662 | 0.930–2.967 | 0.07991 | |||
Location (rectum vs. Colon) (n = 176) | 1.07 | 0.4935–2.318 | 0.8656 | |||
Stage (III/IV vs. I/II) (n = 176) | 1.95 | 1.073–3.543 | 0.0251 | |||
Metastasis presence (n = 155) | 3.398 | 1.82–6.343 | 0.0002934 | 3.813 (n = 155) | 2.032–7.156 | 3.08e-05 (2.475e-06) |
Lymph node infiltration (n = 179) | 1.725 | 0.978–3.042 | 0.05665 | |||
Tumor size (T3/T4 vs. T1/T2) (n = 179) | 1.746 | 0.6899–4.417 | 0.206 | |||
MSI vs. MSS (n = 179) | 1.076 | 0.5948–1.947 | 0.8092 | |||
Late stage vs. early stage (n = 164) | 3.876 | 0.9389–16 | 0.04349 | |||
Methylation (methylated vs unmethylated) (n = 165) | ||||||
CEP55 - cg25314624 | 1.3444 | 0.3213–5.626 | 0.6842 | |||
FOXD3 – cg15617155 | ND | |||||
FOXF2 - cg12221475 | 1.893 | 0.8455–4.236 | 0.1146 | |||
GNAO1- cg00866976 | 0.8484 | 0.4304–1.673 | 0.6347 | |||
cg10273340 | 0.8404 | 0.4161–1.697 | 0.6275 | |||
GRIA4 - cg00343633 | 0.4816 | 0.1483–1.563 | 0.2138 | |||
cg03225817 | 0.6222 | 0.1924–2.012 | 0.4238 | |||
cg07972135 | 0.6185 | 0.2206–1.734 | 0.3564 | |||
cg23559689 | 0.6887 | 0.1662–2.853 | 0.605 | |||
KCNA5 - cg16897114 | 1.91 | 0.4558–8.002 | 0.3682 | |||
Expression (upregulated vs down-regulated) | ||||||
CEP55 | 1.089 | 0.3344–3.549 | 0.8871 | |||
FOXD3 | 1.859 | 0.4483–7.711 | 0.3853 | |||
FOXF2 | ND | |||||
GNAO1 | 0.9207 | 0.2222–3.815 | 0.9092 | |||
GRIA4 | 3.409 | 0.8084–14.38 | 0.07561 | |||
KCNA5 | 1.859 | 0.4483–7.711 | 0.3853 |